Astellas Pharma Inc. (ALPMF)
Chart Events
Performance Outlook
| Previous Close | 14.70 |
| Open | 15.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 14.70 - 14.70 |
| 52 Week Range | 13.50 - 17.95 |
| Volume | 400 |
| Avg. Volume | 2,408 |
| Market Cap | 28.163B |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | 21.55 |
| EPS (TTM) | 0.69 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.39 (2.62%) |
| Ex-Dividend Date | Sep 29, 2020 |
| 1y Target Est | N/A |
- PR Newswire
Astellas' XOSPATA® (gilteritinib) Meets Overall Survival Endpoint in COMMODORE Trial of Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that a Phase 3 confirmatory trial of XOSPATA® (gilteritinib) in patients with relapsed (disease that has returned) or refractory (resistant to treatment) FLT3 mutation-positive (FLT3mut+) acute myeloid leukemia (AML) met its primary endpoint of overall survival (OS) compared to chemotherapy at a planned interim analysis.
- PR Newswire
Astellas Garners New Indication & New Product Formulation Approvals From U.S. FDA for Children with Neurogenic Detrusor Overactivity (NDO)
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) approved Myrbetriq® (mirabegron extended-release tablets) for the treatment of NDO in pediatric patients aged three years and older who weigh 35 kg or more, and Myrbetriq® Granules (mirabegron for extended-release oral suspension) for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged three years and older. The FDA also granted pediatric exclusivity for Myrbetriq, resulting in an additional six month period of market exclusivity.
- PR Newswire
Astellas Receives Positive CHMP Opinion for XTANDIâ„¢ (enzalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending an additional indication for the oral once-daily therapy XTANDITM (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC, also known as metastatic castration-sensitive prostate cancer or mCSPC).1 Men diagnosed with mHSPC tend to have a poor prognosis, with a median survival of approximately 3-4 years, underscoring the need for new treatment options.2
